AnHorn Medicines (安宏生醫), a biopharmaceutical company focused on developing protein degradation therapeutics and leveraging an artificial intelligence (AI) platform to accelerate drug discovery, has successfully completed a Phase I clinical trial in the United States for its innovative candidate AH-001, developed through its proprietary AI drug design platform. The trial results showed that all dose groups exhibited excellent safety and tolerability, with no drug-related adverse events observed. This milestone marks the first successful Phase I trial of an AI-generated drug from Taiwan, further validating AnHorn’s AI platform for efficient drug design and clinical feasibility.

AI-Enabled Innovative Drug Design Confirms Clinical Safety

AH-001 is a novel small-molecule protein degrader, applied topically, that selectively targets androgen receptors (AR) associated with male pattern baldness, blocking the underlying hair loss pathology. Preclinical studies had already demonstrated its promising safety profile and efficacy potential. The Phase I trial further confirmed that AH-001 is well tolerated in both healthy volunteers and patients with androgenetic alopecia. Compared to conventional oral hormonal therapies, AH-001 avoids systemic side effects such as sexual dysfunction and hormonal imbalance, offering higher convenience and safety for long-term use and laying a solid foundation for subsequent dose optimization and efficacy trials.

High Global Demand for Male Pattern Hair Loss Treatment Calls for Innovative Solutions

Androgenetic alopecia is the most common chronic hair loss disorder worldwide. According to the International Society of Hair Restoration Surgery (ISHRS), around 50% of men experience some degree of hair loss by age 50, and approximately 40% of women are affected postpartum or during menopause. Lifestyle changes and increasing environmental stress have contributed to a trend of earlier onset, with growing numbers of people aged 20 to 40 facing appearance-related anxiety and self-confidence challenges.

Current clinical treatments such as Finasteride and Minoxidil have been on the market for over 20 years, but only about 30–40% of patients report satisfaction. Limitations include:

• Long-term use required to maintain effect; hair often returns to baseline within months after discontinuation.
  
• Oral medications may cause sexual dysfunction, depression, and other side effects.
  
• Topical formulations can cause scalp irritation or unwanted hair growth elsewhere.
  
• Limited treatment options for female patients.
  

There is a strong need for novel, safe, long-term therapies with innovative mechanisms, and AH-001 has been developed to address this unmet medical need.

AI-Generated Drug Offers New Protein Degradation Strategy

AH-001 employs AI-driven drug design with a protein degradation mechanism, selectively eliminating androgen receptor (AR) proteins. Its high specificity, safety, and ease of topical application position it as a potential new treatment option for individuals aged 20–50 concerned about appearance, confidence, and professional image.

Global Market Potential Exceeds $1 Billion, Licensing and Clinical Plans Underway

The target market for AH-001 is male pattern hair loss. According to market research by Grand View Research, the global market for androgenetic alopecia treatment is projected to grow at a compound annual growth rate of 8.45%, reaching $4.76 billion by 2030. AnHorn Medicines is actively planning Phase II clinical trials while pursuing global licensing and strategic partnerships to accelerate clinical development and commercialization.

Dr. Lin Chu-Chiang (林助強), Chairman and CEO of AnHorn Medicines, stated:
"The successful completion of the U.S. Phase I trial confirms that AI-generated drugs can not only demonstrate innovation during the design phase but also achieve safety and feasibility in clinical studies. This represents a major milestone in AI drug development. AnHorn will accelerate AH-001 into Phase II trials and actively expand international collaborations to maximize the global impact of this AI-designed drug from Taiwan."

(Source: Research Center for Biotechnology and Medicine Policy, RBMP)

Resource: 安宏生醫AI新藥AH-001完成美國一期臨床試驗，展現優異安全性與耐受性